Pharmaceutical major Pfizer will likely seek the US Food and Drug Administration's emergency authorisation to administer its coronavirus vaccine among children between the ages of 2 and 11 in September, the media reported. By early next week, the company is expected to get FDA approval for emergency use of its vaccine in children 12 to 15 years old.

It is planning to apply for full approval of the vaccine for use in people from ages 16 to 85, this month, The New York Times reported. The pharma major will also have clinical trial data on the safety of its vaccine in pregnant women by early August. The FDA is preparing to make Covid-19 vaccines "accessible to additional, younger populations", Jen Psaki, the White House press secretary, was quoted as saying at a news conference on Tuesday, the report said.